14 reports of this reaction
3.2% of all MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, manufactured by Haleon US Holdings LLC. There are 14 FDA adverse event reports linking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL to FATIGUE. This represents approximately 3.2% of all 436 adverse event reports for this drug.
Patients taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 14 FDA reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.2% of all adverse event reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience fatigue while taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.